Nebenwirkungen · Conbriza
CONBRIZA 20 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 6
HOS-209632 · Präparat HOS-154337
*In the osteoporosis treatment trial in 7,492 evaluable subjects (mean age=66 years), the bazedoxifene-treated women had an increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism and retinal vein thrombosis). The rate per 1,000 women-years through the 3-year study period was 2.86 in the bazedoxifene 20 mg group and 1.76 in the placebo group, and through the 5-year study period was 2.34 in the bazedoxifene 20 mg group and 1.56 in the placebo group. The rate per 1,000 women-years through the 7 year study period was 2.06 in the bazedoxifene 20 mg group and 1.36 in the placebo group. The rate of VTE was highest in the first year with a relative risk of 2.69. After 3 years the relative risk was 1.63 and after a 5 year study period the relative risk was 1.50. After 7 year study period the relative risk was 1.51 (see section 5.1). Other venous thromboembolic events could also occur.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-20T02:00:00Z · SHA-256 1c409a8a8e5a5d9f881382d3102b23f5a4c7f5222a930c0873e9e92636b8ccc8 · Passage dabd2f49e71bb658edaa376b5a0ac960babf31b41ba5335c30ff3c792b90ce6c · Zeichen 4247–5163 im Abschnitt